使用长效注射抗精神病药物的患者的受体占用率变化和精神状态之间的相关性:MIDILIA试点研究
James R O'Neill1,2,3, Christopher Wilson2, Mark A Horowitz4,5
1School of Medicine, University of Leeds, UK.
BJPsych open
|September 12, 2025
概括
在抗精神病剂剂量周期期间,多巴胺D2受体占用率的更快降低可能会使积极的精神病症状恶化. 较慢的减少可能有助于最大限度地减少这些影响,这表明受体占用率变化和症状出现之间存在联系.
科学领域:
- 精神病学和药理学 精神病学和药理学
- 神经科学是一个神经科学.
- 临床精神药理学 临床精神药理学
背景情况:
- 降低抗精神病药物剂量的最佳速度尚未确立.
- 事证据表明,在下一个长效注射抗精神病剂剂量之前,潜在的精神状态可能会恶化.
- 了解这些波动可能会告知触发精神病症状的受体占用率变化.
研究的目的:
- 研究精神病症状与长效注射抗精神病药物的血度 (和估计的受体占用) 之间的关系.
- 探索多巴胺D2受体占用率的变化如何影响抗精神病剂剂量循环期间的精神状态.
主要方法:
- 一项纵向研究追踪精神状态的变化,在储存flupentixol和zuclopenthixol的剂量周期内进行.
- 利用正负综合征量表 (PANSS) 来监测全球心理状态,分为五个领域.
- 基于高峰和低谷度的血试验计算的条状D2占用率.
主要成果:
- 十名参与者的初步发现表明,全球精神状态下降和D2占用率下降之间的相关性.
- 较快的D2占用减少与"积极"和"抵抗"PANSS域的恶化有关 (分别为p=0.047和p=0.018).
- 在PANSS得分变化和D2占用率的绝对减少之间没有发现显著的关系.
结论:
- 观察性研究设计对于这个研究领域来说是可行的和实用的.
- 较快的D2受体占用率降低可能会增加积极精神病症状和易怒的风险.
- 较慢的D2占用减少可能会减轻这些不良影响;需要进一步的研究来确认.
更多相关视频
相关概念视频
Quantitative Aspects of Drug-Receptor Interaction
1.7K
The receptor occupancy theory connects a drug's response to the number of occupied receptors. With higher drug concentrations, more receptors are occupied, leading to increased responses. The formation of drug-receptor complexes involves association and dissociation rates, which reach equilibrium when the forward and backward reactions are equal. The equilibrium association constant (Ka) and its inverse, the equilibrium dissociation constant (Kd), indicate drug affinity. Higher Ka and lower...
1.7K
Psychosis: Goals of Pharmacotherapy
476
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
476
Drug Therapy
246
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
246
Psychosis and Antipsychotic Drugs: Overview
820
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic...
820
Therapeutic Drug Monitoring: Affecting Factors
202
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
202
Drug Product Performance: In Vitro–In Vivo Correlation
234
In pharmaceutical development, it's crucial to establish a predictive in vitro–in vivo correlation (IVIVC) for two or more formulations to gain a comprehensive understanding of release properties. IVIVC reduces the need for costly in vivo studies and facilitates the establishment of meaningful dissolution specifications with significant cost savings and decreased regulatory burden. Furthermore, a meaningful IVIVC should predict Cmax and AUC within 20%, aligning with FDA guidance while...
234


